MedTrace Logo

A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

NCT00823940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-07-07

No results posted yet for this study

Summary

The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GSK1362885

5 - 100mg of GSK1362885 or placebo

DRUG

GSK1362885

100 - 600mg or placebo

DRUG

Glucagon

0.5mg IV bolus

DRUG

Glucagon + GSK1362885

0.5mg Glucagon IV bolus + selected dose of GSK1362885

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-13
Primary Completion
2009-04-27
Completion
2009-04-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823940 on ClinicalTrials.gov